Four Versus Six Cycles of CHOP Chemotherapy in Combination with Six Applications of Rituximab in Patients with Aggressive B-cell Lymphoma with Favourable Prognosis (FLYER): a Randomised, Phase 3, Non-Inferiority Trial Viola Poeschel , Gerhard Held , Marita Ziepert , Mathias Witzens-Harig , Harald Holte , Lorenz Thurner , Peter Borchmann , Andreas Viardot , Martin Soekler , Ulrich Keller , Christian Schmidt , Lorenz Truemper , Rolf Mahlberg , Reinhard Marks , Heinz-Gert Hoeffkes , Bernd Metzner , Judith Dierlamm , Norbert Frickhofen , Mathias Haenel , Andreas Neubauer , Michael Kneba , Francesco Merli , Alessandra Tucci , Peter de Nully Brown , Massimo Federico , Eva Lengfelder , Alice di Rocco , Ralf Trappe , Andreas Rosenwald , Christian Berdel , Martin Maisenhoelder , Ofer Shpilberg , Josif Amam , Konstantinos Christofyllakis , Frank Hartmann , Niels Murawski , Stephan Stilgenbauer , Maike Nickelsen , Gerald Wulf , Bertram Glass , Norbert Schmitz , Bettina Altmann , Markus Loeffler , Michael Pfreundschuh The Lancet（2019）
AI 理解论文
溯源树
样例
